Cytophage Technologies (TSXV:CYTO) Tax Provision : C$0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Cytophage Technologies Tax Provision?

Cytophage Technologies's tax provision for the three months ended in Mar. 2024 was C$0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2024 was C$0.00 Mil.

Cytophage Technologies Tax Provision Historical Data

The historical data trend for Cytophage Technologies's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytophage Technologies Tax Provision Chart

Cytophage Technologies Annual Data

Trend

Dec21

Dec22

Dec23

Tax Provision

Cytophage Technologies Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Tax Provision	Get a 7-Day Free Trial			-	-	-	-	-

Cytophage Technologies Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

Cytophage Technologies (TSXV:CYTO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytophage Technologies Ltd (TSXV:CYTO) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Cytophage Technologies Ltd is a Canadian biotechnology company that uses molecular genetic techniques and synthetic biology to create effective bacteriophages to address bacterial challenges affecting animal health, human health, and food security. Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals, and plants. To combat dangerous bacteria company generates phages to address specific bacterial infections, including strains resistant to antibiotics. It has also developed a 'phage-display' methodology to develop vaccine-like products using bacteriophages for a number of potential applications in human and animal health.